Efficacy of injectable platelet rich fibrin (iPRF) as a root biomodification agent in the management of RTI gingival recession- a double blinded randomised control trial.

Gingival recession is defined as apical migration of the gingival margin in the enamel-cement border towards the apex and subsequent exposure of the root surface . Among the several methods that have been developed to treat gingival recession, it is based on the case selection and material of choice that makes it success. Researchers have investigated the root coverage effects of various biomodification agents, including Emdogain, various root development regulators, laser treatments, growth factors, and thrombocyte-rich plasma. Injectable PRF (I-PRF) is the liquid form of PRF. I-PRF is a bioactive agent obtained by low-speed centrifugation, and it has the capacity to stimulate tissue regeneration. i-PRF is generally used in regenerative treatments, with good outcomes. One of the components that make up I-PRF is fibronectin which is an extracellular glycoprotein with a high molecular weight (approximately 440 kDa). Application of fibronectin to root surfaces improves cellular proliferation from the periodontal ligament towards the supracrestal parts. Hence the study was undertaken to evaluate the efficacy of i-PRF as a root biomodification agent in treatment of RT I gingival recession along with coronally advanced flap.